Pomerantz Law Firm Files Class Action Against Regencell Bioscience Holdings Amid Market Turmoil

Class Action Lawsuit Against Regencell Bioscience Holdings

In recent developments, Pomerantz LLP, a widely recognized law firm, has filed a class action lawsuit against Regencell Bioscience Holdings Limited, better known as Regencell, as well as specific officers of the company. This lawsuit, registered as case number 26-cv-01602 in the United States District Court for the District of Maryland, targets a class of individuals and entities that acquired Regencell securities from October 28, 2024, to October 31, 2025.

The lawsuit seeks to recover damages that stem from alleged violations of federal securities laws. The core allegations revolve around breaches of sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alongside Rule 10b-5. If you purchased Regencell's securities during the specified Class Period, you have until June 23, 2026, to seek the role of Lead Plaintiff.

Overview of Regencell

Regencell describes itself as an early-stage bioscience company that is focused on developing traditional Chinese medicine aimed at treating attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), both conditions which currently lack definitive cures. The company claims that while standard treatments primarily serve to alleviate symptoms, its novel approach endeavors to address the root causes of these neurocognitive disorders.

As of their latest annual report, it was revealed that a significant portion—approximately 88.8%—of Regencell's shares were controlled by its directors and executives, with founder and CEO Yat-Gai Au owning a substantial majority of these shares.

Share Price Volatility

A striking aspect of the lawsuit is the volatility observed in Regencell’s share price. For much of the Class Period, shares traded below $0.30. However, beginning in early May 2025, an astonishing surge sent shares soaring to an unprecedented $78.00 by mid-June 2025—approximately a 48,650% increase from the start of the Class Period. This meteoric rise was followed by a drastic fall, with prices dropping to a range of just above $20.00 shortly thereafter.

Despite the massive fluctuations in share prices, Regencell recorded no substantial public disclosures that could have justified such movements. The company has only a handful of employees, no active products available for sale, and has continually sustained losses from its operations. The minimal amount allocated for research and development raises further questions about the sustainability of the company's operations given their ambitious claims about curing chronic disorders.

Regencell's market capitalization peaked at approximately $14 billion during the height of this price fluctuation—a value that baffled analysts and investors alike, particularly when considering their lack of revenue and tangible products.

Allegations of Misleading Statements

The class action claims that during the Class Period, Regencell’s executives made materially false and misleading statements about the company’s risks and operations, hiding their vulnerability to market manipulation and significant financial risks. Furthermore, the lawsuit asserts that this misinformation exposed the investors to the possibility of regulatory action and potential legal consequences.

The turning point in this saga came on October 31, 2025, when Regencell announced that it had received a subpoena from the U.S. Department of Justice (DOJ), indicating an investigation into the company’s stock trading activities. This pivotal moment triggered a sharp decline in the share price, causing a significant loss for investors who had been led to believe in Regencell’s soaring value.

Pomerantz LLP’s Legacy

Pomerantz LLP has a longstanding reputation in addressing corporate fraud and misconduct, with a history exceeding 85 years since its founding by Abraham L. Pomerantz. With a proven track record of recovering substantial damages for class members, the firm is committed to defending the rights of investors who have fallen victim to securities fraud.

For those interested in joining this class action or seeking further information, a copy of the complaint is available at Pomerantz Law Firm's website. Interested parties can also reach out to attorney Danielle Peyton directly at [email protected] or by phone at 646-581-9980.

In conclusion, the Pomerantz-led class action against Regencell marks a significant moment in the scrutiny of corporate actions and accountability in the biosciences sector, particularly regarding the legitimacy of claims made by companies in emerging markets.

For investors and followers of this case, monitoring the developments and outcomes of this lawsuit will be imperative, as it could set a crucial precedent in the realm of securities litigation.